Form 10-Q REXAHN PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Roth Affirms Rexahn Pharma (RNN) at 'Buy'; Broad POC Program Initiation, Archexin Data in mRCC on Tap
November 3, 2015 11:49 AM ESTRoth Capital affirms Rexahn Pharma (NYSE: RNN) with a Buy rating and $3 price target after the company announced Q3 results and offered an update on operations today.
Analyst Joseph Pantginis noted that Rexahn's Q3 loss of $0.02 per share was flat with the firm's... More
Rexahn Pharma (RNN) Tops Q3 EPS by 1c
November 3, 2015 10:30 AM ESTRexahn Pharma (NYSE: RNN) reported Q3 EPS of ($0.02), $0.01 better than the analyst estimate of ($0.03).
"Rexahn made important progress during the third quarter presenting new interim clinical data for Supinoxin and RX-3117 at an international medical conference, said Peter D. Suzdak, Ph.D., Chief Executive... More
